PharmaVigilant Introduces Study Building Solution, I-BUILDER 2.0
Westborough, MA-December 14, 2009
PharmaVigilant has introduced I-Builder 2.0, an enhanced study-building solution that was designed to ease the study build process and technology transfer for sponsors. I-Builder 2.0 provides the industry with a user interface for building EDC studies. I-Builder can support multiple users for building all phases of clinical research studies from simple studies to global, multicenter or adaptive study designs.
“The study design serves as the solid foundation for successful program execution. Studies not based on the proper architecture suffer from cracks and data issues that result in costly delays,” said James DeSanti, Founder and Chief Executive Officer, PharmaVigilant. “With I-Builder 2.0, PharmaVigilant is offering [a]...technology that makes it simple for sponsors to build innovative and adaptive study designs...using fewer internal resources. And the new interface will ensure that sponsors can integrate I-Builder into their organizations with minimal training, and little need for any on-going support.”
I-Builder is a Web based, thin client application that can support multiple users for their global study design needs, and offers a study builder module enabling sponsors to build trials from simple to complex adaptive trials for Phase I-IV.
In addition to I-Builder 2.0, the company offers a full suite of clinical trial technology offerings including Electronic Data Capture (EDC), data warehousing, Electronic Trial Master File System (eTMF), Remote Source Document Verification (rSDV), study administration and an automated site payment system. PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies. The technology has supported more than 200,000 patients in 14 countries across North America, Europe, Asia, and Australia and continues to expand rapidly.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
